Abcellera Biologics is trading 4.62% up now at $11.10 in pre-market, aligned with stronger futures, particularly the Nasdaq Composite’s 0.97% gain, rather than a newly announced company-specific catalyst.
- On August 24, it fell 6.27% to $10.61.
- Investors are still weighing the recently priced $200 million offering.
- Its latest official news listing shows no newer August 25 announcement.